Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioNTech, ADR
BioNTech SE ADR rises Monday, outperforms market
The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.28% to 5,718.57 and the Dow Jones Industrial Average DJIA rising 0.
BioNTech SE (BNTX) Receives a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a
Jefferies Upgrades BioNTech SE - Depositary Receipt () (BNTX)
Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) from Hold to Buy. Analyst Price Forecast Suggests 8.06% Downside As of August 25,
BioNTech SE ADR falls Friday, underperforms market
The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.09% to 42,063.
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The
4d
on MSN
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
Zacks.com on MSN
16h
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
12d
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
3d
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
6d
Decoding BioNTech's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
Zacks.com on MSN
10d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Pharmabiz
1d
EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine
EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...
10d
Forecasting The Future: 8 Analyst Projections For BioNTech
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
EuropaWire
2d
Pfizer and BioNTech’s Omicron KP.2-Adapted COVID-19 Vaccine Receives Positive EU Opinion, Awaiting Approval
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
Hosted on MSN
6d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Covid-19
Pfizer
European Union
Moderna
Novavax
Feedback